Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances 16. July 2018, section EUDA news
9. June 2026 New health risks for Europeans in a fast-moving drug market People who use drugs in Europe are facing new health risks as drug markets evolve rapidly and become more complex. This...
